{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:45:00Z","timestamp":1771469100819,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T00:00:00Z","timestamp":1545696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Oprozomib is an oral, second\u2010generation, irreversible proteasome inhibitor currently in clinical development for haematologic malignancies, including multiple myeloma and other malignancies. Oprozomib is a rare example of a small molecule drug that demonstrates cytochrome P450 (CYP) mRNA suppression. This unusual property elicits uncertainty regarding the optimal approach for predicting its drug\u2013drug interaction (DDI) risk. The current study aims to understand DDI potential during early clinical development of oprozomib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To support early development of oprozomib (e.g. inclusion\/exclusion criteria, combination study design), we used human hepatocyte data and physiologically\u2010based pharmacokinetic (PBPK) modelling to predict its CYP3A4\u2010mediated DDI potential. Subsequently, a clinical DDI study using midazolam as the substrate was conducted in patients with advanced malignancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The clinical DDI study enrolled a total of 21 patients, 18 with advanced solid tumours. No patient discontinued oprozomib due to a treatment\u2010related adverse event. The PBPK model prospectively predicted oprozomib 300\u00a0mg would not cause a clinically relevant change in exposure to CYP3A4 substrates (\u226430%), which was confirmed by the results of this clinical DDI study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results indicate oprozomib has a low potential to inhibit the metabolism of CYP3A4 substrates in humans. The study shows that cultured human hepatocytes are a more reliable system for DDI prediction than human liver microsomes for studying this class of compounds. Developing a PBPK model prior to a clinical DDI study has been valuable in supporting clinical development of oprozomib.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13817","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T22:04:40Z","timestamp":1542233080000},"page":"530-539","source":"Crossref","is-referenced-by-count":12,"title":["Physiologically\u2010based pharmacokinetic modelling to predict oprozomib CYP3A drug\u2013drug interaction potential in patients with advanced malignancies"],"prefix":"10.1111","volume":"85","author":[{"given":"Ying","family":"Ou","sequence":"first","affiliation":[{"name":"Amgen Inc.  South San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4281-3977","authenticated-orcid":false,"given":"Yang","family":"Xu","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia","family":"Gore","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus  Aurora CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Donald","family":"Harvey","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University  Atlanta GA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Mita","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Medical Center  Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyriakos P.","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"South Texas Accelerated Research Therapeutics  San Antonio TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengping","family":"Wang","sequence":"additional","affiliation":[{"name":"Amgen Inc.  South San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Richard E.","family":"Cutler","sequence":"additional","affiliation":[{"name":"Onyx Pharmaceuticals, Inc., an Amgen subsidiary  South San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn E.","family":"Pinchasik","sequence":"additional","affiliation":[{"name":"Amgen Inc.  South San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,12,25]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Amgen Inc.Carfilzomib (KYPROLIS) prescribing information.2017. Available athttp:\/\/pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi\u2010amgen\u2010com\/kyprolis\/kyprolis_pi.pdf(last accessed 12 January 2018)."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm801329v"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-276626"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood.V126.23.378.378","article-title":"Oprozomib, pomalidomide, and dexamethasone (OPomd) in patients (Pts) with relapsed and\/or refractory multiple myeloma (RRMM): Initial results of a phase 1b study (NCT01999335)","volume":"126","author":"Shah J","year":"2015","journal-title":"Blood"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1182\/blood.V124.21.3453.3453","article-title":"Oprozomib and dexamethasone in patients with relapsed and\/or refractory multiple myeloma: initial results from the dose escalation portion of a phase 1b\/2, multicenter, open\u2010label study [abstract]","volume":"124","author":"Hari PN","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood.V124.21.1715.1715","article-title":"Updated results from a multicenter, open\u2010label, dose\u2010escalation phase 1b\/2 study of single\u2010agent oprozomib in patients with Waldenstr\u00f6m Macroglobulinemia (WM)","volume":"124","author":"Siegel DS","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.V124.21.34.34","article-title":"Clinical profile of single\u2010agent oprozomib in patients (Pts) with multiple myeloma (MM): updated results from a multicenter, open\u2010label, dose escalation phase 1b\/2 study","volume":"124","author":"Vij R","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2110.2110"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0327-x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.075226"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3323"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.298"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.30"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-016-0059-9"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90160-0"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.025494"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2009.12.002"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.047662"},{"key":"e_1_2_9_20_1","unstructured":"Simcyp.A guide for IVIVE and PBPK\/PD modeling using the Simcyp population based simulator. Sheffield: Simcyp Ltd 2012;231\u2013249."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.79"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.22.313"},{"key":"e_1_2_9_23_1","unstructured":"Clinical Drug Interaction Studies \u2013 Study Design Data Analysis and Clinical Implications. Guidance for Industry. Draft Guidance. FDA 2017. Available athttp:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM292362.pdf(last accessed 12 January 2018)."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12003"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1830"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.128"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.917"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13877"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.026187"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.044628"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(94)90482-0"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10104"},{"key":"e_1_2_9_34_1","unstructured":"Aidarex Pharmaceuticals LLC.Dexamethasone prescribing information 2017. Available athttps:\/\/www.drugs.com\/pro\/dexamethasone.html(last accessed 12 January 2018)."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13817","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13817","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13817","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T10:29:18Z","timestamp":1694341758000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,25]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1111\/bcp.13817"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13817","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,25]]}}}